Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making

JAMA - Journal of the American Medical Association

Volumn 312, Issue 10, 2014, Pages 995-996

  Thompson, Ian M ^a   Leach, Robin J ^a   Ankerst, Donna P ^a,b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC TEST; EARLY DIAGNOSIS; HUMAN; LIFE EXPECTANCY; OBSERVATIONAL STUDY; PATIENT DECISION MAKING; PATIENT PREFERENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN TESTING; QUALITY OF LIFE; RISK ASSESSMENT; SEPSIS; SHORT SURVEY; AGED; ARTICLE; BIOPSY; BLOOD; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATIENT PARTICIPATION; PROSTATE; PROSTATE TUMOR; UTILIZATION REVIEW;

AGED; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PATIENT PREFERENCE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84907010995     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.9680     Document Type: Short Survey

References (10)

1. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
2. Schröder FH, Hugosson J, Roobol MJ, et al ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
3. Andriole GL, Crawford ED, Grubb RL III, et al PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
4. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956-962.
5. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250-1261.
6. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(1 suppl):S12-S17.
7. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534.
8. Individualized Risk Assessment of Prostate Cancer. http://www.myprostatecancerrisk.com. Accessed July 25, 2014.
9. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362-1327.
10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.